Hernia News and Research

RSS

A hernia is protrusion of an organ or the muscular wall of an organ through the cavity that normally contains it. A hiatal hernia occurs when the stomach protrudes upwards into the mediastinum through the esophageal opening in the diaphragm.

Gore commences treatment in Europe with new 25 cm VIABAHN Endoprosthesis

W. L. Gore & Associates announced the treatment of the first European patients with the new 25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, the longest length stent-graft available in Europe. Piotr Kasprzak, from the Department of Vascular Surgery at the Klinikum der Universität in Regensburg, Germany, and Thomas Zeller, MD, from the Department of Angiology at the Herz-Zentrum in Bad Krozingen, Germany successfully treated patients using the Gore device.

23 Sep 2010

GORE C3 Delivery System enables repositioning of stent graft during procedure for AAA

W. L. Gore & Associates (Gore) today announced the first clinical uses of the GORE C3 Delivery System to deploy the GORE EXCLUDER AAA Endoprosthesis as a minimally invasive treatment for patients suffering from an abdominal aortic aneurysm (AAA).

16 Sep 2010

NUH receives DSRB approval for new comparative study with TIGR Matrix Surgical Mesh

Novus Scientific Pte. Ltd today announced that the National University Hospital (NUH), Singapore has received Domain Specific Review Board (DSRB i.e. IRB equivalent) provisional approval for a new study: Abdominal Wall Closure After Lipectomy, TRAM/DIEP Flap - Comparison of TIGR (100% Resorbable) vs Polypropylene (Permanent) Mesh.

13 Sep 2010

Athersys signs agreement with RTI Biologics for MAPC technology access

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, and Athersys Inc. a leader in regenerative medicine and cell therapy research and development, announced today an agreement under which Athersys will provide RTI access to its Multipotent Adult Progenitor Cell (MAPC) technologies.

13 Sep 2010

RTI Biologics, Zimmer ink global distribution agreement for dental biologic implants

RTI Biologics Inc., a leading provider of orthopedic and other biologic implants, announced today the signing of an exclusive, 10-year distribution agreement with Zimmer Dental Inc. for biologic implants for the dental market worldwide.

8 Sep 2010

3D MRI enhances visualization, displays fetal anatomy and diagnosing problems

Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.

26 Aug 2010

RTI, Medtronic take several steps to continuously improve their relationship

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, in response to inquiries regarding Medtronic's announced acquisition of Osteotech stated today that the relationship between Medtronic and RTI Biologics continues to be strong, with no changes near-term.

18 Aug 2010

Gore announces first implantation in IDE clinical study of ACUSEAL Vascular Graft in hemodialysis patients

W. L. Gore & Associates reported that the first patient, in an Investigational Device Exemption (IDE) clinical study evaluating the self sealing GORE® ACUSEAL Vascular Graft in patients on hemodialysis, has been surgically implanted with the device. The successful surgical procedure was performed on July 29, 2010 at Greenville Hospital System in Greenville, South Carolina. Less than 24 hours after the device was implanted it was successfully cannulated or punctured for initial hemodialysis access.

13 Aug 2010

Atrium awarded 3-year national contract from Premier for surgical mesh products

Atrium Medical Corporation, pioneering advancements in biological, mechanical and therapeutic solutions for soft tissue reinforcement, is proud to announce that the company was awarded a three-year national contract from Premier Purchasing Partners L.P., the group purchasing organization of Premier, Inc. (Charlotte, NC).

10 Aug 2010

Sleeve gastrectomy for weight loss surgery with no scars

Surgeons at the University of California, San Diego School of Medicine have achieved what is believed to be the nation's first stomach reduction via the mouth. The novel weight loss procedure, known as a sleeve gastrectomy, reduces the stomach to 20 percent of its original size. The smaller stomach leads to less caloric intake and increased feelings of fullness. This is the first time in the U.S. that the excess stomach has been removed through the mouth rather than a large open incision.

10 Aug 2010

RTI Biologics second-quarter worldwide revenues in sports medicine increase 14%

RTI Biologics Inc., a leading processor of orthopedic and other biologic implants, reported operating results for the second quarter ended June 30, 2010.

5 Aug 2010

First successful procedures in Australia with GORE DrySeal Sheath for aortic aneurysms

W.L. Gore & Associates (Gore) announced today the first clinical cases in Australia involving the revolutionary GORE® DrySeal Sheath. The sheath aids in minimally invasive treatment of patients with abdominal aortic aneurysms (AAA) utilizing the GORE® EXCLUDER® AAA Endoprosthesis and thoracic aortic aneurysms (TAA) utilizing the GORE® TAG® Thoracic Endoprosthesis.

3 Aug 2010

Clinicians in rural hospitals demonstrate high standard of care to patients: Study

Smaller, rural hospitals may be quicker and more efficient at implementing surgical safety initiatives than their larger, urban counterparts, and are capable of providing a standard of surgical care that is at par with major hospitals that provide a comprehensive array of care services, according to an 18-month series of studies led by researchers from the University of Louisville Department of Surgery.

28 Jul 2010

Gore provides update on REDUCE Clinical Study of HELEX Septal Occluder for PFO closure

W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.

9 Jul 2010

Landmark study compares oral and transvaginal NOTES to traditional laparoscopy

As part of the only U.S. prospective multicenter clinical trial to compare natural orifice translumenal endoscopic surgery to laparoscopy, surgeons at the University of California, San Diego School of Medicine have performed the trial's first oral gallbladder removal. This landmark study will evaluate whether or not NOTES is safe and as effective as traditional laparoscopic surgery.

8 Jul 2010

Gore receives European CE Mark approval for 25 cm GORE VIABAHN Endoprosthesis

W. L. Gore & Associates today announced that it has received European CE Mark approval for the 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface. The new 25 cm GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface is the longest length stent-graft available, designed to cover more of the lesion in the Superficial Femoral Artery potentially reducing the need for multiple devices.

1 Jul 2010

Biomerix receives FDA 510(k) Clearance to market Ventral Hernia Repair Mesh

Biomerix Corporation announced today that it has received U.S. Food and Drug Administration 510(k) Clearance to market its Biomerix Ventral Hernia Repair Mesh, the latest addition to its innovative portfolio of soft tissue repair devices. The Biomerix Ventral Hernia Repair Mesh, with two distinctly different sides, is the first and only device featuring the Biomerix Biomaterial on one side, designed to promote tissue ingrowth, and a resorbable protective film on the other side, designed to minimize tissue attachment to the device in case of direct contact with the viscera.

1 Jul 2010

Merck's DULERA Inhalation Aerosol for asthma receives FDA approval

Merck today announced that the U.S. Food and Drug Administration (FDA) has approved DULERA® (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol, a new fixed-dose combination asthma treatment for patients 12 years of age and older. DULERA is not indicated for the relief of acute bronchospasm. DULERA combines an inhaled corticosteroid (mometasone furoate) with a long-acting beta2-agonist (formoterol fumarate).

24 Jun 2010

Methodist surgeons study transvaginal removal of donor kidney

Surgeons at The Methodist Hospital in Houston are studying a new way to make kidney donation safer, less invasive and almost scar free for women by using a new technique that removes kidneys transvaginally.

22 Jun 2010

PolyTouch Medical's PatchAssist device receives FDA clearance

PolyTouch Medical Ltd., a leading developer of laparoscopic soft tissue prosthetic placement technologies, today announced that it has received broad FDA 510(k) clearance to commercialize PatchAssist. PatchAssist is an innovative laparoscopic surgical instrument that enables accurate and rapid delivery and placement of soft tissue prosthetics for a variety of procedures, including laparoscopic ventral hernia repair.

21 Jun 2010